Will Walmart avoid disclosing GLP-1 supply issues by 29 October 2026?
Posted 2026-08-15 — 75 days before the deadline, stated before the outcome.
Walmart is a major American retail corporation that sells pharmaceutical products. This forecast concerns whether the company will publicly report specific disruptions or price changes for GLP-1 medications within a defined timeframe.
The claim
Walmart will not issue a public statement or filing disclosing a supply disruption or price increase for GLP-1 products within 75 days.
Reasoning trace
- Upstream shock: Glp-1 (z=4.4); Walmart exposed via 'uses' edge
Evidence so far
2 confirming · 0 denying signals · 1 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 16 times since mint (last on 2026-09-15) — 99% at mint → 78% today.
What to watch
- milestone Walmart publishes its Q3 2026 earnings report and associated earnings call transcript within the specified window observed
- milestone Walmart files its quarterly 10-Q report for the period ending September 30, 2026, with the SEC without disclosing GLP-1 supply issues
- precondition Walmart files its quarterly 10-Q report with the SEC for the period ending in the window
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.